DexCom

Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.

Beta Bionics is a biotechnology company based in Boston, Massachusetts, focused on advancing diabetes care through its innovative bionic pancreas system, known as the iLet. Founded in 2015, the company has developed a dual-chamber infusion pump that precisely delivers insulin and glucagon, allowing for autonomous management of blood sugar levels. The iLet has received breakthrough designation for its various configurations, including insulin-only, glucagon-only, and bihormonal uses, particularly in conjunction with Zealand Pharma’s dasiglucagon, a stable glucagon analog in a ready-to-use solution. By reducing the burden and cost associated with diabetes management, Beta Bionics aims to improve the quality of life for individuals living with diabetes.

TypeZero is leveraging more than 10 years of clinical trials, research, and innovation to develop the inControl Diabetes Management Platform to improve and simplify the lives of people with diabetes.

Nintamed GmbH & Co. KG is a distribution company based in Mainz, Germany, specializing in glucose monitoring systems for diabetic patients and healthcare providers. The company operates primarily in Germany, Switzerland, and Austria, offering products that include a continuous glucose monitoring system and pen needles for insulin administration. As of May 2016, Nintamed functions as a subsidiary of DexCom, Inc. Through its innovative products, Nintamed aims to enhance diabetes management and support patients in maintaining their blood sugar levels effectively.

SweetSpot is a health data company focused on improving the use of data in the treatment of diabetes. We specialize in turning raw output from patient devices into reports that are powerful for researchers, health care providers, and patients. In clinics or from home SweetSpot performs all data extraction and analysis, relieving frustration with multiple interfaces, drivers and data formats. Our goal is to help clinics make the most of their time and their patient’s data.